Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim

Inclusion Criteria: * males or females of any ethnic origin between 18 and 55 years of age * subjects weighing between 50 and 100 kg, with a body mass index (BMI) between 18 and 32 kg/m2. * subjects in good health, as determined by a medical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations Exclusion Criteria: * Female subjects of child-bearing potential. * Male subjects (or their partners) who are not willing to use appropriate contraception during the study and for 3 months after end of dosing. * Female subjects who are pregnant or lactating. * Subjects who have received any prescribed systemic or topical medication within 14 days of first dose administration * Subjects who have used any non-prescribed systemic or topical medication within 7 days of first dose administration * Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of first dose administration * Subjects with or history of clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatry, respiratory, metabolic, endocrine, ocular haematological or other major disorders as determined by the investigator